ESR1 and breast carcinoma: The group of HER2-low breast carcinomas represents a newly defined entity in the field, thanks to the observation that treatment with trastuzumab duocarmazine led to partial response in 28% and 40% of patients with HER2-low ER-positive and ER-negative breast cancer, respectively (13).